BLFS 📈 BioLife Solutions - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062W2044
BLFS: Biopreservation Media, Bioproduction Tools, Cryogenic Freezers, Storage Containers
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington. Web URL: https://www.biolifesolutions.com
Additional Sources for BLFS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BLFS Stock Overview
Market Cap in USD | 1,217m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 1989-11-22 |
BLFS Stock Ratings
Growth 5y | 27.4% |
Fundamental | -22.1% |
Dividend | - |
Rel. Strength Industry | 1196 |
Analysts | 4.8/5 |
Fair Price Momentum | 26.20 USD |
Fair Price DCF | 2.37 USD |
BLFS Dividends
No Dividends PaidBLFS Growth Ratios
Growth Correlation 3m | 65% |
Growth Correlation 12m | 89.1% |
Growth Correlation 5y | -15.9% |
CAGR 5y | 10.96% |
CAGR/Mean DD 5y | 0.24 |
Sharpe Ratio 12m | 1.08 |
Alpha | 19.16 |
Beta | 1.63 |
Volatility | 63.30% |
Current Volume | 125.3k |
Average Volume 20d | 325.2k |
What is the price of BLFS stocks?
As of December 28, 2024, the stock is trading at USD 27.03 with a total of 125,285 shares traded.
Over the past week, the price has changed by +3.52%, over one month by -0.11%, over three months by +11.83% and over the past year by +62.24%.
As of December 28, 2024, the stock is trading at USD 27.03 with a total of 125,285 shares traded.
Over the past week, the price has changed by +3.52%, over one month by -0.11%, over three months by +11.83% and over the past year by +62.24%.
Is BioLife Solutions a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, BioLife Solutions is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -22.09 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BLFS as of December 2024 is 26.20. This means that BLFS is currently overvalued and has a potential downside of -3.07%.
Neither. Based on ValueRay Fundamental Analyses, BioLife Solutions is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -22.09 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BLFS as of December 2024 is 26.20. This means that BLFS is currently overvalued and has a potential downside of -3.07%.
Is BLFS a buy, sell or hold?
BioLife Solutions has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy BLFS.
BioLife Solutions has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy BLFS.
- Strong Buy: 8
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for BLFS stock price target?
According to ValueRays Forecast Model, BLFS BioLife Solutions will be worth about 29.7 in December 2025. The stock is currently trading at 27.03. This means that the stock has a potential upside of +9.69%.
According to ValueRays Forecast Model, BLFS BioLife Solutions will be worth about 29.7 in December 2025. The stock is currently trading at 27.03. This means that the stock has a potential upside of +9.69%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 29.8 | 10.2% |
Analysts Target Price | 24.4 | -9.6% |
ValueRay Target Price | 29.7 | 9.7% |